Page last updated: 2024-10-16

adenine and Adenocarcinoma, Basal Cell

adenine has been researched along with Adenocarcinoma, Basal Cell in 48 studies

Research Excerpts

ExcerptRelevanceReference
"Twelve patients with recurrent, metastatic, or inoperable gastric adenocarcinoma were enrolled in an Illinois Cancer Center phase II trial of amonafide (nafidimide), a novel compound that acts as a DNA intercalator."9.07Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial. ( Bauman, A; Benson, AB; Blough, RR; Carroll, RB; French, SL; Kilton, LJ; Mullane, MR; Schilsky, RL; Wade, JL, 1994)
"To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial."9.07Phase II study of amonafide in advanced pancreatic adenocarcinoma. ( Abbruzzese, JL; Ajani, JA; Bradof, JE; Daugherty, K; Levin, B; Linke, K; Pazdur, R; Winn, R, 1991)
"Amonafide, a benzisoquinoline-1,3-dione with anti-tumor activity in preclinical screens, was administered to patients with recurrent or metastatic bidimensionally measurable colorectal cancer."9.07Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer. ( Comis, RL; Hudes, GR; O'Dwyer, PJ; Ozols, RF; Paul, AR; Walczak, J, 1991)
"Altered cyclin D1 (CD1), a cell cycle regulator, may play an important role in imparting aggressive nature to esophageal adenocarcinoma (EAC)."7.74Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. ( Ajani, JA; Chao, CK; Correa, A; Ensor, J; Hittelman, WN; Izzo, JG; Luthra, R; Pan, J; Swisher, SG; Wu, TT; Wu, X, 2007)
"Amonafide, 300 mg/m2, was administered intravenously over 1 hour daily for 5 consecutive days."6.67Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study. ( Alberts, DS; Craig, JB; Liu, PY; Malviya, VK; O'Sullivan, J; O'Toole, R; Rosenoff, S; Surwit, E; Ward, JH; Yu, A, 1994)
"Amonafide is a substituted benzisoquinolinedione that exerts its cytotoxicity through effects on macromolecular synthesis and intercalation of DNA."6.67Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study. ( Brown, TD; Craig, JB; Einstein, AB; Fleming, T; Goodman, PJ; Macdonald, JS, 1993)
"Twelve patients with recurrent, metastatic, or inoperable gastric adenocarcinoma were enrolled in an Illinois Cancer Center phase II trial of amonafide (nafidimide), a novel compound that acts as a DNA intercalator."5.07Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial. ( Bauman, A; Benson, AB; Blough, RR; Carroll, RB; French, SL; Kilton, LJ; Mullane, MR; Schilsky, RL; Wade, JL, 1994)
"To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial."5.07Phase II study of amonafide in advanced pancreatic adenocarcinoma. ( Abbruzzese, JL; Ajani, JA; Bradof, JE; Daugherty, K; Levin, B; Linke, K; Pazdur, R; Winn, R, 1991)
"Amonafide, a benzisoquinoline-1,3-dione with anti-tumor activity in preclinical screens, was administered to patients with recurrent or metastatic bidimensionally measurable colorectal cancer."5.07Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer. ( Comis, RL; Hudes, GR; O'Dwyer, PJ; Ozols, RF; Paul, AR; Walczak, J, 1991)
" We found that in a gastric adenocarcinoma cell line GTL-16, where MET activity is deregulated due to receptor overexpression, two different MET inhibitors PHA665752 and EMD1214063 lead to cell death paralleled by the induction of autophagy."3.79Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells. ( Aebersold, DM; Bladt, F; Blaukat, A; Fey, MF; Humbert, M; Medová, M; Tschan, MP; Zimmer, Y, 2013)
"Novel ruthenium-letrozole complexes have been prepared, and cell viability of two human cancer cell types (breast and glioblastoma) was determined."3.78New ruthenium(II)-letrozole complexes as anticancer therapeutics. ( Castonguay, A; Doucet, C; Juhas, M; Maysinger, D, 2012)
" The aim of this study is to investigate the effects of combined autophagy inhibitor 3-methyladenine (3-MA) on the radiosensitivity of human adenocarcinoma A549 cells in hypoxia condition."3.78[The effect of autophagy on the radioresistance of human adenocarcinoma A549 cell in hypoxia condition]. ( Cai, A; Li, L; Li, Y; Xu, L; Zhong, X, 2012)
"Altered cyclin D1 (CD1), a cell cycle regulator, may play an important role in imparting aggressive nature to esophageal adenocarcinoma (EAC)."3.74Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. ( Ajani, JA; Chao, CK; Correa, A; Ensor, J; Hittelman, WN; Izzo, JG; Luthra, R; Pan, J; Swisher, SG; Wu, TT; Wu, X, 2007)
" The highest tested dose of ibrutinib, 560 mg once daily, was combined with a fixed dose of pembrolizumab 200 mg every 3 weeks for the phase 2 portion."3.01A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. ( Carballido, E; Imanirad, I; Kim, DW; Kim, RD; Martinez, M; Mehta, R; Schell, MJ; Strosberg, J; Tan, E; Yu, J; Zhou, JM, 2021)
"Amonafide was given at a dose of 225 mg/m2 intravenously daily for 5 days."2.67Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study. ( Ahmann, F; Blumenstein, B; Craig, JB; Crawford, ED; Eisenberger, M; Marshall, ME; Thompson, IM, 1994)
"Amonafide, 300 mg/m2, was administered intravenously over 1 hour daily for 5 consecutive days."2.67Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study. ( Alberts, DS; Craig, JB; Liu, PY; Malviya, VK; O'Sullivan, J; O'Toole, R; Rosenoff, S; Surwit, E; Ward, JH; Yu, A, 1994)
"Amonafide is a substituted benzisoquinolinedione that exerts its cytotoxicity through effects on macromolecular synthesis and intercalation of DNA."2.67Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study. ( Brown, TD; Craig, JB; Einstein, AB; Fleming, T; Goodman, PJ; Macdonald, JS, 1993)
"Oesophageal cancer is the fifth most frequent cause of cancer death world wide and most of these cancers occur in developing countries."2.40Molecular precursor lesions in oesophageal cancer. ( Hainaut, P; Montesano, R, 1998)
"Upon metabolic perturbation, prostate cancer cell lines upregulate MTAP and this correlates with recovery of SAM levels."1.43The essential role of methylthioadenosine phosphorylase in prostate cancer. ( Affronti, HC; Bistulfi, G; Foster, BA; Gillard, B; Karasik, E; Mohler, J; Morrison, C; Phillips, JG; Smiraglia, DJ, 2016)
"The bleak prognosis associated with pancreatic cancer (PDAC) drives the need for the development of novel treatment methodologies."1.42Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer. ( Guillen, KP; Harrison, RG; Kurkjian, C; Restuccia, A, 2015)
"In contrast, colorectal cancers with codon 12 aspartic acid substitutions accounted for most of the distant hematogenous deposits (P < 0."1.29Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. ( Christensen, S; Finkelstein, SD; Sayegh, R; Swalsky, PA, 1993)
" With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer."1.28Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer. ( Berger, MZ; Dimaggio, JJ; Gralla, RJ; Heelan, RT; Kris, MG; Marks, LD; Potanovich, LM, 1991)

Research

Studies (48)

TimeframeStudies, this research(%)All Research%
pre-199013 (27.08)18.7374
1990's13 (27.08)18.2507
2000's5 (10.42)29.6817
2010's13 (27.08)24.3611
2020's4 (8.33)2.80

Authors

AuthorsStudies
Halim, AA1
Alsayed, B1
Embarak, S1
Yaseen, T1
Dabbous, S1
Fontaine, O1
Dueluzeau, R1
Raibaud, P1
Chabanet, C1
Popoff, MR1
Badoual, J1
Gabilan, JC1
Andremont, A1
Gómez, L1
Andrés, S1
Sánchez, J1
Alonso, JM1
Rey, J1
López, F1
Jiménez, A1
Yan, Z1
Zhou, L1
Zhao, Y3
Wang, J6
Huang, L2
Hu, K1
Liu, H4
Wang, H3
Guo, Z1
Song, Y1
Huang, H4
Yang, R1
Owen, TW1
Al-Kaysi, RO1
Bardeen, CJ1
Cheng, Q1
Wu, S1
Cheng, T1
Zhou, X1
Wang, B4
Zhang, Q4
Wu, X3
Yao, Y3
Ochiai, T1
Ishiguro, H2
Nakano, R2
Kubota, Y2
Hara, M1
Sunada, K1
Hashimoto, K1
Kajioka, J1
Fujishima, A1
Jiao, J3
Gai, QY3
Wang, W2
Zang, YP2
Niu, LL2
Fu, YJ3
Wang, X4
Yao, LP1
Qin, QP1
Wang, ZY1
Liu, J4
Aleksic Sabo, V1
Knezevic, P1
Borges-Argáez, R1
Chan-Balan, R1
Cetina-Montejo, L1
Ayora-Talavera, G1
Sansores-Peraza, P1
Gómez-Carballo, J1
Cáceres-Farfán, M1
Jang, J1
Akin, D1
Bashir, R1
Yu, Z1
Zhu, J2
Jiang, H1
He, C2
Xiao, Z1
Xu, J2
Sun, Q1
Han, D1
Lei, H1
Zhao, K2
Zhu, L1
Li, X4
Fu, H2
Wilson, BK1
Step, DL1
Maxwell, CL1
Gifford, CA1
Richards, CJ1
Krehbiel, CR1
Warner, JM1
Doerr, AJ1
Erickson, GE1
Guretzky, JA1
Rasby, RJ1
Watson, AK1
Klopfenstein, TJ1
Sun, Y4
Liu, Z3
Pham, TD1
Lee, BK1
Yang, FC1
Wu, KH1
Lin, WP1
Hu, MK1
Lin, L3
Shao, J1
Sun, M1
Xu, G1
Zhang, X6
Xu, N1
Wang, R1
Liu, S1
He, H1
Dong, X2
Yang, M2
Yang, Q1
Duan, S1
Yu, Y2
Han, J2
Zhang, C3
Chen, L2
Yang, X1
Li, W3
Wang, T2
Campbell, DA1
Gao, K1
Zager, RA1
Johnson, ACM1
Guillem, A1
Keyser, J1
Singh, B1
Steubl, D1
Schneider, MP1
Meiselbach, H1
Nadal, J1
Schmid, MC1
Saritas, T1
Krane, V1
Sommerer, C1
Baid-Agrawal, S1
Voelkl, J1
Kotsis, F1
Köttgen, A1
Eckardt, KU1
Scherberich, JE1
Li, H4
Yao, L2
Sun, L3
Zhu, Z1
Naren, N1
Zhang, XX2
Gentile, GL1
Rupert, AS1
Carrasco, LI1
Garcia, EM1
Kumar, NG1
Walsh, SW1
Jefferson, KK1
Guest, RL1
Samé Guerra, D1
Wissler, M1
Grimm, J1
Silhavy, TJ1
Lee, JH2
Yoo, JS1
Kim, Y1
Kim, JS2
Lee, EJ1
Roe, JH1
Delorme, M1
Bouchard, PA1
Simon, M1
Simard, S1
Lellouche, F1
D'Urzo, KA1
Mok, F1
D'Urzo, AD1
Koneru, B1
Lopez, G1
Farooqi, A1
Conkrite, KL1
Nguyen, TH1
Macha, SJ1
Modi, A1
Rokita, JL1
Urias, E1
Hindle, A1
Davidson, H1
Mccoy, K1
Nance, J1
Yazdani, V1
Irwin, MS1
Yang, S1
Wheeler, DA1
Maris, JM1
Diskin, SJ1
Reynolds, CP1
Abhilash, L1
Kalliyil, A1
Sheeba, V1
Hartley, AM2
Meunier, B2
Pinotsis, N1
Maréchal, A2
Xu, JY1
Genko, N1
Haraux, F1
Rich, PR1
Kamalanathan, M1
Doyle, SM1
Xu, C1
Achberger, AM1
Wade, TL1
Schwehr, K1
Santschi, PH1
Sylvan, JB1
Quigg, A1
Leong, W1
Xu, W2
Gao, S1
Zhai, X1
Wang, C2
Gilson, E1
Ye, J1
Lu, Y1
Yan, R1
Zhang, Y6
Hu, Z1
You, Q1
Cai, Q1
Yang, D1
Gu, S1
Dai, H1
Zhao, X1
Gui, C1
Gui, J1
Wu, PK1
Hong, SK1
Starenki, D1
Oshima, K1
Shao, H1
Gestwicki, JE1
Tsai, S1
Park, JI1
Wang, Y7
Zhao, R1
Gu, Z1
Dong, C2
Guo, G1
Li, L5
Barrett, HE1
Meester, EJ1
van Gaalen, K1
van der Heiden, K1
Krenning, BJ1
Beekman, FJ1
de Blois, E1
de Swart, J1
Verhagen, HJ1
Maina, T1
Nock, BA1
Norenberg, JP1
de Jong, M1
Gijsen, FJH1
Bernsen, MR1
Martínez-Milla, J1
Galán-Arriola, C1
Carnero, M1
Cobiella, J1
Pérez-Camargo, D1
Bautista-Hernández, V1
Rigol, M1
Solanes, N1
Villena-Gutierrez, R1
Lobo, M1
Mateo, J1
Vilchez-Tschischke, JP1
Salinas, B1
Cussó, L1
López, GJ1
Fuster, V1
Desco, M1
Sanchez-González, J1
Ibanez, B1
van den Berg, P1
Schweitzer, DH1
van Haard, PMM1
Geusens, PP1
van den Bergh, JP1
Zhu, X1
Huang, X2
Xu, H2
Yang, G2
Lin, Z1
Salem, HF1
Nafady, MM1
Kharshoum, RM1
Abd El-Ghafar, OA1
Farouk, HO1
Domiciano, D1
Nery, FC1
de Carvalho, PA1
Prudente, DO1
de Souza, LB1
Chalfun-Júnior, A1
Paiva, R1
Marchiori, PER1
Lu, M2
An, Z1
Jiang, J2
Li, J7
Du, S1
Zhou, H1
Cui, J1
Wu, W1
Liu, Y7
Song, J1
Lian, Q1
Uddin Ahmad, Z1
Gang, DD1
Konggidinata, MI1
Gallo, AA1
Zappi, ME1
Yang, TWW1
Johari, Y1
Burton, PR1
Earnest, A1
Shaw, K1
Hare, JL1
Brown, WA1
Kim, GA1
Han, S1
Choi, GH1
Choi, J1
Lim, YS1
Gallo, A1
Cancelli, C1
Ceron, E1
Covino, M1
Capoluongo, E1
Pocino, K1
Ianiro, G1
Cammarota, G1
Gasbarrini, A1
Montalto, M1
Somasundar, Y1
Lu, IC1
Mills, MR1
Qian, LY1
Olivares, X1
Ryabov, AD1
Collins, TJ1
Zhao, L1
Doddipatla, S1
Thomas, AM1
Nikolayev, AA1
Galimova, GR1
Azyazov, VN1
Mebel, AM1
Kaiser, RI1
Guo, S1
Yang, P1
Yu, X2
Wu, Y2
Zhang, H1
Yu, B2
Han, B1
George, MW1
Moor, MB1
Bonny, O1
Langenberg, E1
Paik, H1
Smith, EH1
Nair, HP1
Hanke, I1
Ganschow, S1
Catalan, G1
Domingo, N1
Schlom, DG1
Assefa, MK1
Wu, G2
Hayton, TW1
Becker, B1
Enikeev, D1
Netsch, C1
Gross, AJ1
Laukhtina, E1
Glybochko, P1
Rapoport, L1
Herrmann, TRW1
Taratkin, M1
Dai, W1
Shi, J2
Carreno, J1
Kloner, RA1
Pickersgill, NA1
Vetter, JM1
Kim, EH1
Cope, SJ1
Du, K1
Venkatesh, R1
Giardina, JD1
Saad, NES1
Bhayani, SB1
Figenshau, RS1
Eriksson, J1
Landfeldt, E1
Ireland, S1
Jackson, C1
Wyatt, E1
Gaudig, M1
Stancill, JS1
Happ, JT1
Broniowska, KA1
Hogg, N1
Corbett, JA1
Tang, LF1
Bi, YL1
Fan, Y2
Sun, YB1
Wang, AL1
Xiao, BH1
Wang, LF1
Qiu, SW1
Guo, SW1
Wáng, YXJ1
Sun, J2
Chu, S1
Pan, Q1
Li, D2
Zheng, S2
Ma, L1
Wang, L3
Hu, T1
Wang, F1
Han, Z1
Yin, Z1
Ge, X1
Xie, K1
Lei, P1
Dias-Santagata, D1
Lennerz, JK1
Sadow, PM1
Frazier, RP1
Govinda Raju, S1
Henry, D1
Chung, T1
Kherani, J1
Rothenberg, SM1
Wirth, LJ1
Marti, CN1
Choi, NG1
Bae, SJ1
Ni, L1
Luo, X1
Dai, T1
Yang, Y3
Lee, R1
Fleischer, AS1
Wemhoff, AP1
Ford, CR1
Kleppinger, EL1
Helms, K1
Bush, AA1
Luna-Abanto, J1
García Ruiz, L1
Laura Martinez, J1
Álvarez Larraondo, M1
Villoslada Terrones, V1
Dukic, L1
Maric, N1
Simundic, AM1
Chogtu, B1
Ommurugan, B1
Thomson, SR1
Kalthur, SG1
Benidir, M1
El Massoudi, S1
El Ghadraoui, L1
Lazraq, A1
Benjelloun, M1
Errachidi, F1
Cassar, M1
Law, AD1
Chow, ES1
Giebultowicz, JM1
Kretzschmar, D1
Salonurmi, T1
Nabil, H1
Ronkainen, J1
Hyötyläinen, T1
Hautajärvi, H1
Savolainen, MJ1
Tolonen, A1
Orešič, M1
Känsäkoski, P1
Rysä, J1
Hakkola, J1
Hukkanen, J1
Zhu, N1
Li, Y5
Du, Q1
Hao, P1
Cao, X1
Li, CX1
Zhao, S1
Luo, XM1
Feng, JX1
Gonzalez-Cotto, M1
Guo, L1
Karwan, M1
Sen, SK1
Barb, J1
Collado, CJ1
Elloumi, F1
Palmieri, EM1
Boelte, K1
Kolodgie, FD1
Finn, AV1
Biesecker, LG1
McVicar, DW1
Qu, F1
Deng, Z1
Xie, Y2
Tang, J3
Chen, Z2
Luo, W1
Xiong, D1
Zhao, D1
Fang, J1
Zhou, Z1
Niu, PP1
Song, B1
Xu, YM1
Zhang, Z2
Qiu, N1
Yin, J1
Zhang, J3
Guo, W1
Liu, M2
Liu, T2
Chen, D5
Luo, K1
He, Z2
Zheng, G1
Xu, F1
Sun, W1
Yin, F1
van Hest, JCM1
Du, L2
Shi, X1
Kang, S1
Duan, W1
Zhang, S2
Feng, J2
Qi, N1
Shen, G1
Ren, H1
Shang, Q1
Zhao, W2
Yang, Z2
Jiang, X2
Alame, M1
Cornillot, E1
Cacheux, V1
Tosato, G1
Four, M1
De Oliveira, L1
Gofflot, S1
Delvenne, P1
Turtoi, E1
Cabello-Aguilar, S1
Nishiyama, M1
Turtoi, A1
Costes-Martineau, V1
Colinge, J1
Guo, Q1
Quan, M1
Dong, J1
Bai, J1
Han, R1
Cai, Y1
Lv, YQ1
Chen, Q1
Lyu, HD1
Deng, L1
Zhou, D1
Xiao, X1
De Langhe, S1
Billadeau, DD1
Lou, Z1
Zhang, JS1
Xue, Z1
Shen, XD1
Gao, F1
Busuttil, RW1
Kupiec-Weglinski, JW1
Ji, H1
Otano, I1
Alvarez, M1
Minute, L1
Ochoa, MC1
Migueliz, I1
Molina, C1
Azpilikueta, A1
de Andrea, CE1
Etxeberria, I1
Sanmamed, MF1
Teijeira, Á1
Berraondo, P1
Melero, I1
Zhong, Z1
Xie, X1
Yu, Q1
Zhou, C1
Liu, C2
Liu, W1
Chen, W1
Yin, Y1
Li, CW1
Hsu, JL1
Zhou, Q1
Hu, B1
Fu, P1
Atyah, M1
Ma, Q2
Xu, Y1
Dong, Q1
Hung, MC1
Ren, N1
Huang, P1
Liao, R1
Chen, X3
Cao, Q1
Yuan, X1
Nie, W1
Yang, J2
Shao, B1
Ma, X1
Bi, Z1
Liang, X1
Tie, Y1
Mo, F1
Xie, D1
Wei, Y1
Wei, X2
Dokla, EME1
Fang, CS1
Chu, PC1
Chang, CS1
Abouzid, KAM1
Chen, CS1
Blaszczyk, R1
Brzezinska, J1
Dymek, B1
Stanczak, PS1
Mazurkiewicz, M1
Olczak, J1
Nowicka, J1
Dzwonek, K1
Zagozdzon, A1
Golab, J1
Golebiowski, A1
Xin, Z1
Himmelbauer, MK1
Jones, JH1
Enyedy, I1
Gilfillan, R1
Hesson, T1
King, K1
Marcotte, DJ1
Murugan, P1
Santoro, JC1
Gonzalez-Lopez de Turiso, F1
Pedron, J1
Boudot, C1
Brossas, JY1
Pinault, E1
Bourgeade-Delmas, S1
Sournia-Saquet, A1
Boutet-Robinet, E1
Destere, A1
Tronnet, A1
Bergé, J1
Bonduelle, C1
Deraeve, C1
Pratviel, G1
Stigliani, JL1
Paris, L1
Mazier, D1
Corvaisier, S1
Since, M1
Malzert-Fréon, A1
Wyllie, S1
Milne, R1
Fairlamb, AH1
Valentin, A1
Courtioux, B1
Verhaeghe, P1
Fang, X1
Gao, M1
Gao, H1
Bi, W1
Tang, H1
Cui, Y1
Zhang, L3
Fan, H1
Yu, H1
Mathison, CJN1
Chianelli, D1
Rucker, PV1
Nelson, J1
Roland, J1
Huang, Z2
Xie, YF1
Epple, R1
Bursulaya, B1
Lee, C1
Gao, MY1
Shaffer, J1
Briones, S1
Sarkisova, Y1
Galkin, A1
Li, N1
Li, C2
Hua, S1
Kasibhatla, S1
Kinyamu-Akunda, J1
Kikkawa, R1
Molteni, V1
Tellew, JE1
Jin, X1
Pang, B1
Liu, Q2
Liu, X3
Huang, Y2
Josephine Fauci, A1
Ma, Y1
Soo Lee, M1
Yuan, W1
Gao, R1
Qi, H1
Zheng, W1
Yang, F2
Chua, H1
Wang, K1
Ou, Y1
Huang, M1
Zhu, Y1
Yu, J2
Tian, J1
Zhao, M1
Hu, J1
Yao, C1
Zhang, B1
Usawachintachit, M1
Tzou, DT1
Washington, SL1
Hu, W1
Chi, T1
Sorensen, MD1
Bailey, MR1
Hsi, RS1
Cunitz, BW1
Simon, J1
Wang, YN1
Dunmire, BL1
Paun, M1
Starr, F1
Lu, W1
Evan, AP1
Harper, JD1
Han, G1
Rodrigues, AE1
Fouladvand, F1
Falahi, E1
Asbaghi, O1
Abbasnezhad, A1
Anigboro, AA1
Avwioroko, OJ1
Cholu, CO1
Sonei, A1
Fazelipour, S1
Kanaani, L1
Jahromy, MH1
Jo, K1
Hong, KB1
Suh, HJ1
Park, JH2
Shin, E1
Park, E1
Kouakou-Kouamé, CA1
N'guessan, FK1
Montet, D1
Djè, MK1
Kim, GD1
González-Fernández, D1
Pons, EDC1
Rueda, D1
Sinisterra, OT1
Murillo, E1
Scott, ME1
Koski, KG1
Shete, PB1
Gonzales, R1
Ackerman, S1
Cattamanchi, A1
Handley, MA1
Li, XX1
Xiao, SZ1
Gu, FF1
He, WP1
Ni, YX1
Han, LZ1
Heffernan, JK1
Valgepea, K1
de Souza Pinto Lemgruber, R1
Casini, I1
Plan, M1
Tappel, R1
Simpson, SD1
Köpke, M1
Nielsen, LK1
Marcellin, E1
Cen, YK1
Lin, JG1
Wang, YL1
Wang, JY1
Liu, ZQ1
Zheng, YG1
Spirk, D1
Noll, S1
Burnier, M1
Rimoldi, S1
Noll, G1
Sudano, I1
Penzhorn, BL1
Oosthuizen, MC1
Kobos, LM1
Alqatani, S1
Ferreira, CR1
Aryal, UK1
Hedrick, V1
Sobreira, TJP1
Shannahan, JH1
Gale, P1
Singhroy, DN1
MacLean, E1
Kohli, M1
Lessem, E1
Branigan, D1
England, K1
Suleiman, K1
Drain, PK1
Ruhwald, M1
Schumacher, S1
Denkinger, CM1
Waning, B1
Van Gemert, W1
Pai, M1
Myers, RK1
Bonsu, JM1
Carey, ME1
Yerys, BE1
Mollen, CJ1
Curry, AE1
Douglas, TA1
Alinezhadbalalami, N1
Balani, N1
Schmelz, EM1
Davalos, RV1
Kamaldinov, T1
Erndt-Marino, J1
Levin, M1
Kaplan, DL1
Hahn, MS1
Heidarimoghadam, R1
Farmany, A1
Lee, JJ1
Kang, J1
Park, S1
Cho, JH1
Oh, S1
Park, DJ1
Perez-Maldonado, R1
Cho, JY1
Park, IH1
Kim, HB1
Song, M1
Mfarrej, B1
Jofra, T1
Morsiani, C1
Gagliani, N1
Fousteri, G1
Battaglia, M1
Giuliano, C1
Levinger, I1
Vogrin, S1
Neil, CJ1
Allen, JD1
Lv, Y1
Yuan, R1
Cai, B1
Bahrami, B1
Chowdhury, AH1
Yang, C2
Qiao, Q1
Liu, SF1
Zhang, WH1
Kolano, L1
Knappe, D1
Volke, D1
Sträter, N1
Hoffmann, R1
Coussens, M1
Calders, P1
Lapauw, B1
Celie, B1
Banica, T1
De Wandele, I1
Pacey, V1
Malfait, F1
Rombaut, L1
Vieira, D1
Angel, S1
Honjol, Y1
Gruenheid, S1
Gbureck, U1
Harvey, E1
Merle, G1
Seo, G1
Lee, G1
Kim, MJ1
Baek, SH1
Choi, M1
Ku, KB1
Lee, CS1
Jun, S1
Park, D1
Kim, HG1
Kim, SJ1
Lee, JO1
Kim, BT1
Park, EC1
Kim, SI1
Ende, M1
Kirkkala, T1
Loitzenbauer, M1
Talla, D1
Wildner, M1
Miletich, R1
Criado, A1
Lavela, P1
Tirado, JL1
Pérez-Vicente, C1
Kang, D1
Feng, D2
Fang, Z1
Wei, F1
De Clercq, E1
Pannecouque, C1
Zhan, P1
Guo, Y1
Shen, Y1
Wang, Q2
Kawazoe, Y1
Jena, P1
Sun, Z1
Li, Z2
Liang, H1
Xu, X1
Ma, G1
Huo, X1
Church, JS1
Chace-Donahue, F1
Blum, JL1
Ratner, JR1
Zelikoff, JT1
Schwartzer, JJ1
Fiseha, T1
Tamir, Z1
Yao, W1
Wang, P1
Mi, K1
Cheng, J1
Gu, C1
Huang, J2
Sun, HB1
Xing, WQ1
Liu, XB1
Zheng, Y1
Yang, SJ1
Wang, ZF1
Liu, SL1
Ba, YF1
Zhang, RX1
Liu, BX1
Fan, CC1
Chen, PN1
Liang, GH1
Yu, YK1
Wang, HR1
Li, HM1
Li, ZX1
Lalani, SS1
Anasir, MI1
Poh, CL1
Khan, IT1
Nadeem, M1
Imran, M1
Khalique, A1
Raspini, B1
Porri, D1
De Giuseppe, R1
Chieppa, M1
Liso, M1
Cerbo, RM1
Civardi, E1
Garofoli, F1
Monti, MC1
Vacca, M1
De Angelis, M1
Cena, H1
Kong, D1
Han, X1
Zhou, Y3
Xue, H1
Zhang, W1
Ruan, Z1
Li, S2
Noer, PR1
Kjaer-Sorensen, K1
Juhl, AK1
Goldstein, A1
Ke, C1
Oxvig, C1
Duan, C1
Kong, F1
Lin, S1
Wang, Z2
Bhattacharya, R1
Mazumder, D1
Yan, X1
Ma, C1
Tang, Y1
Kong, X1
Lu, J1
Zhang, M1
Vital-Jacome, M1
Cazares-Granillo, M1
Carrillo-Reyes, J1
Buitron, G1
Jacob, SI1
Douair, I1
Maron, L1
Ménard, G1
Rusjan, P1
Sabioni, P1
Di Ciano, P1
Mansouri, E1
Boileau, I1
Laveillé, A1
Capet, M1
Duvauchelle, T1
Schwartz, JC1
Robert, P1
Le Foll, B1
Xia, Y1
Chen, S1
Luo, M1
Wu, J1
Cai, S1
He, Y2
Garbacz, P1
Misiak, M1
Jackowski, K1
Yuan, Q1
Sherrell, PC1
Chen, J2
Bi, X1
Nutho, B1
Mahalapbutr, P1
Hengphasatporn, K1
Pattaranggoon, NC1
Simanon, N1
Shigeta, Y1
Hannongbua, S1
Rungrotmongkol, T1
Caffrey, PJ1
Kher, R1
Bian, K1
Delaney, S1
Xue, J1
Wu, P1
Xu, L2
Yuan, Y1
Luo, J1
Ye, S1
Ustriyana, P1
Wei, B1
Raee, E1
Hu, Y1
Wesdemiotis, C1
Sahai, N1
Kaur, A1
Nigam, K1
Srivastava, S1
Tyagi, A1
Dang, S1
Millar, JE1
Bartnikowski, N1
Passmore, MR1
Obonyo, NG1
Malfertheiner, MV1
von Bahr, V1
Redd, MA1
See Hoe, L1
Ki, KK1
Pedersen, S1
Boyle, AJ1
Baillie, JK1
Shekar, K1
Palpant, N1
Suen, JY1
Matthay, MA1
McAuley, DF1
Fraser, JF1
Settles, JA1
Gerety, GF1
Spaepen, E1
Suico, JG1
Child, CJ1
Oh, BL1
Lee, JS1
Lee, EY1
Lee, HY1
Yu, HG1
Leslie, I1
Boos, LA1
Larkin, J1
Pickering, L1
Lima, HK1
Vogel, K1
Hampel, D1
Wagner-Gillespie, M1
Fogleman, AD1
Ferraz, SL1
O'Connor, M1
Mazzucchelli, TG1
Kajiyama, H1
Suzuki, S1
Shimbo, A1
Utsumi, F1
Yoshikawa, N1
Kikkawa, F1
Javvaji, PK1
Dhali, A1
Francis, JR1
Kolte, AP1
Roy, SC1
Selvaraju, S1
Mech, A1
Sejian, V1
DeSilva, S1
Vaidya, SS1
Mao, C1
Akhatayeva, Z1
Cheng, H1
Zhang, G1
Jiang, F1
Meng, X1
Elnour, IE1
Lan, X1
Song, E1
Rohde, S1
Antonides, CFJ1
Muslem, R1
de Woestijne, PCV1
der Meulen, MHV1
Kraemer, US1
Dalinghaus, M1
Bogers, AJJC1
Pourmand, A1
Ghassemi, M1
Sumon, K1
Amini, SB1
Hood, C1
Sikka, N1
Duan, H1
Chen, WP1
Fan, M1
Wang, WP1
Yu, L1
Tan, SJ1
Xin, S1
Wan, LJ1
Guo, YG1
Tanda, S1
Gingl, K1
Ličbinský, R1
Hegrová, J1
Goessler, W1
Li, ZL1
Zhou, YL1
Yan, W1
Luo, L1
Su, ZZ1
Fan, MZ1
Wang, SR1
Zhao, WG1
Xu, D1
Hassan, HM1
Jiang, Z1
Bachmann, KF1
Haenggi, M1
Jakob, SM1
Takala, J1
Gattinoni, L1
Berger, D1
Bentley, RF1
Vecchiarelli, E1
Banks, L1
Gonçalves, PEO1
Thomas, SG1
Goodman, JM1
Mather, K1
Boachie, R1
Anini, Y1
Panahi, S1
Anderson, GH1
Luhovyy, BL1
Nafie, MS1
Arafa, K1
Sedky, NK1
Alakhdar, AA1
Arafa, RK1
Fan, S1
Hu, H1
Liang, J1
Hu, BC1
Wen, Z1
Hu, D1
Liu, YY1
Chu, Q1
Wu, MC1
Lu, X1
Wang, D1
Hu, M1
Shen, H1
Yao, M2
Dahlgren, RA1
Vysloužil, J1
Kulich, P1
Zeman, T1
Vaculovič, T1
Tvrdoňová, M1
Mikuška, P1
Večeřa, Z1
Stráská, J1
Moravec, P1
Balcar, VJ1
Šerý, O1
Qiao, L1
Xiong, X1
Peng, X1
Zheng, J1
Duan, J1
Xiao, W1
Zhou, HY1
Sui, ZY1
Zhao, FL1
Sun, YN1
Wang, HY1
Han, BH1
Jintao, X1
Shasha, Y1
Jincai, W1
Chunyan, L1
Mengya, Y1
Yongli, S1
Rasoanirina, BNV1
Lassoued, MA1
Miladi, K1
Razafindrakoto, Z1
Chaâbane-Banaoues, R1
Ramanitrahasimbola, D1
Cornet, M1
Sfar, S1
Liang, C1
Xing, Q1
Yi, JL1
Zhang, YQ1
Li, CY1
Tang, SJ1
Gao, C1
Sun, X1
Peng, M1
Sun, XF1
Zhang, T1
Shi, JH1
Liao, CX1
Gao, WJ1
Sun, LL1
Gao, Y1
Cao, WH1
Lyu, J1
Yu, CQ1
Wang, SF1
Pang, ZC1
Cong, LM1
Dong, Z1
Wu, F1
Wu, XP1
Jiang, GH1
Wang, XJ1
Wang, BY1
Li, LM1
Pan, L1
Wan, SP1
Yi, HWL1
He, HJ1
Yong, ZP1
Shan, GL1
Weng, TT1
Yan, SQ1
Gao, GP1
Wei, C1
Tao, FB1
Shao, ZH1
Yao, T1
Dong, S1
Shi, S1
Feng, YL1
Zhang, YW1
Wang, SP1
Shi, AX1
Operario, D1
Zhang, ZH1
Zhu, XF1
Zaller, N1
Gao, P1
Sun, YH1
Zhang, HB1
Pilli, VS1
Datta, A1
Dorsey, A1
Liu, B1
Majumder, R1
Philip, PA1
Kim, DW1
Tan, E1
Zhou, JM1
Schell, MJ1
Martinez, M1
Carballido, E1
Mehta, R1
Strosberg, J1
Imanirad, I1
Kim, RD1
Ghaddar, N1
Wang, S1
Woodvine, B1
Krishnamoorthy, J1
van Hoef, V1
Darini, C1
Kazimierczak, U1
Ah-Son, N1
Popper, H1
Johnson, M1
Officer, L1
Teodósio, A1
Broggini, M1
Mann, KK1
Hatzoglou, M1
Topisirovic, I1
Larsson, O1
Le Quesne, J1
Koromilas, AE1
Uekita, T1
Fujii, S1
Miyazawa, Y1
Hashiguchi, A1
Abe, H1
Sakamoto, M1
Sakai, R1
Hu, CW1
Lee, H1
Chen, JL1
Li, YJ1
Chao, MR1
Lee, YR1
So, HS1
Lee, KK1
Lee, SY1
Moon, SR1
Jo, HJ1
Lee, S1
Jeong, K1
Kwon, KB1
Yang, SH1
Bao, LJ1
Jaramillo, MC1
Zhang, ZB1
Zheng, YX1
Zhang, DD1
Yi, XF1
Massó-Vallés, D1
Jauset, T1
Serrano, E1
Sodir, NM1
Pedersen, K1
Affara, NI1
Whitfield, JR1
Beaulieu, ME1
Evan, GI1
Elias, L1
Arribas, J1
Soucek, L1
Guillen, KP1
Restuccia, A1
Kurkjian, C1
Harrison, RG1
Bistulfi, G1
Affronti, HC1
Foster, BA1
Karasik, E1
Gillard, B1
Morrison, C1
Mohler, J1
Phillips, JG1
Smiraglia, DJ1
Khashab, T1
Loghavi, S1
Konoplev, SN1
Samaniego, F1
Yan, L1
Yanan, D1
Donglan, S1
Na, W1
Rongmiao, Z1
Zhifeng, C1
Arakawa, H1
Weng, MW1
Chen, WC1
Tang, MS1
Castonguay, A1
Doucet, C1
Juhas, M1
Maysinger, D1
Cai, A1
Zhong, X1
Humbert, M1
Medová, M1
Aebersold, DM1
Blaukat, A1
Bladt, F1
Fey, MF1
Zimmer, Y1
Tschan, MP1
Speina, E1
Zielińska, M1
Barbin, A1
Gackowski, D1
Kowalewski, J1
Graziewicz, MA1
Siedlecki, JA1
Oliński, R1
Tudek, B1
SUTCLIFFE, EY1
ZEE-CHENG, KY1
CHENG, CC1
ROBINS, RK1
Izzo, JG1
Wu, TT1
Ensor, J1
Luthra, R1
Pan, J1
Correa, A1
Swisher, SG1
Chao, CK1
Hittelman, WN1
Ajani, JA2
Dunzendorfer, U1
Releyea, N1
Whitmore, WF1
Fogh, J1
Balis, ME1
Mullane, MR1
Schilsky, RL1
Carroll, RB1
Wade, JL1
Kilton, LJ1
Blough, RR1
Bauman, A1
French, SL1
Benson, AB1
Marshall, ME1
Blumenstein, B1
Crawford, ED1
Thompson, IM1
Craig, JB3
Eisenberger, M1
Ahmann, F1
Houri, JJ1
Ogier-Denis, E1
Trugnan, G1
Codogno, P1
Terunuma, H1
Hayakashi, T1
Tsuneyoshi, T1
Fujita, M1
Kino, I1
Baba, S1
Malviya, VK1
Liu, PY1
O'Toole, R1
Alberts, DS1
Surwit, E1
Rosenoff, S1
Ward, JH1
Yu, A1
O'Sullivan, J1
Brown, TD1
Goodman, PJ1
Fleming, T1
Macdonald, JS1
Einstein, AB1
Harwood, J1
Tachibana, A1
Davis, R1
Bhattacharyya, NP1
Meuth, M1
Finkelstein, SD1
Sayegh, R1
Christensen, S1
Swalsky, PA1
Leaf, AN1
Neuberg, D1
Schwartz, EL1
Wadler, S1
Ritch, PS1
Dutcher, JP1
Adams, GL1
Montesano, R1
Hainaut, P1
Tsukuda, K1
Tanino, M1
Soga, H1
Shimizu, N1
Shimizu, K1
Fisher, MJ1
Virmani, AK1
Wu, L1
Aplenc, R1
Harper, JC1
Powell, SM1
Rebbeck, TR1
Sidransky, D1
Gazdar, AF1
El-Deiry, WS1
Linke, K1
Pazdur, R1
Abbruzzese, JL1
Winn, R1
Bradof, JE1
Daugherty, K1
Levin, B1
Berger, MZ1
Kris, MG1
Gralla, RJ1
Marks, LD1
Potanovich, LM1
Dimaggio, JJ1
Heelan, RT1
O'Dwyer, PJ1
Paul, AR1
Hudes, GR1
Walczak, J1
Ozols, RF1
Comis, RL1
Jones, SB1
Toews, ML1
Turner, JT1
Bylund, DB1
Karuzina, NP1
Shuvaeva, NI1
Klimanova, ZF1
Antoshechkina, ET1
Larsen, PR1
DeRubertis, F1
Yamashita, K1
Dekker, A1
Field, JB1
Takayasu, H1
Aso, Y1
Okada, K1
Hoshino, Y1
Koiso, K1
Hill, DL3
Wingo, R1
Straight, S1
Allan, PW1
Bennett, LL2
Willoughby, HW1
Maughan, GB1
Tremblay, PC1
Wood, N1
Dixon, GJ1
Dulmadge, EA1
Brockman, RW1
Shaddix, SC1
Adamson, DJ1
Brown, GB1
Sugiura, K1
Cresswell, RM1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I/II Study of Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers[NCT03332498]Phase 1/Phase 240 participants (Actual)Interventional2018-01-24Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Phase I - Recommended Phase II Dose (RP2D)

Standard 3+3 Design: The first cohort will enroll a minimum of 3 participants, according to a standard 3+3 design. If 0 out of the first 3 participants in the first cohort experience a dose-limiting toxicity (DLT), then dose escalation will continue as planned. If 1 out of the first 3 participants experience a DLT, then the cohort will be expanded to a total of 6 participants, and if no more than 1 out of 6 participants experiences a DLT in a given dose cohort, dose escalation will continue as planned. If ≥ 2 DLTs are observed in the first dose cohort, the principle investigator will discuss with Janssen on how to proceed. The DLT evaluation period will be defined as the time from the first dose of pembrolizumab and ibrutinib to 42 days after the first dose or if a participant experiences a DLT within this time period. (NCT03332498)
Timeframe: 42 days post first dose

Interventionmg (Number)
Pembrolizumab and Ibrutinib560

Phase II - Disease Control Rate at 4 Months

Percentage of participants who achieved disease control at 4 months. Disease control rate = Complete Response (CR) + Partial Response (PR) + Stable Disease (SD). Tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and RECIST based immune-related response criteria (irRC). (NCT03332498)
Timeframe: 4 months

Interventionpercentage of participants (Number)
Phase 2: Treatment at RP2D13

Reviews

2 reviews available for adenine and Adenocarcinoma, Basal Cell

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
Molecular precursor lesions in oesophageal cancer.
    Cancer surveys, 1998, Volume: 32

    Topics: Adenine; Adenocarcinoma; Base Pairing; Carcinoma, Squamous Cell; Clone Cells; Disease Progression; E

1998

Trials

9 trials available for adenine and Adenocarcinoma, Basal Cell

ArticleYear
    The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1

    Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P

2016
A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer.
    British journal of cancer, 2021, Volume: 124, Issue:11

    Topics: Adenine; Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2021
Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial.
    Investigational new drugs, 1994, Volume: 12, Issue:3

    Topics: Adenine; Adenocarcinoma; Antineoplastic Agents; Female; Hematologic Diseases; Humans; Imides; Isoqui

1994
Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study.
    American journal of clinical oncology, 1994, Volume: 17, Issue:6

    Topics: Adenine; Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedul

1994
Phase II trial of amonafide in patients with advanced metastatic or recurrent endometrial adenocarcinoma. A Southwest Oncology Group study.
    American journal of clinical oncology, 1994, Volume: 17, Issue:1

    Topics: Adenine; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans;

1994
Phase II trial of amonafide in advanced colorectal cancer: a SouthWest Oncology Group study.
    Anti-cancer drugs, 1993, Volume: 4, Issue:1

    Topics: Adenine; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms

1993
An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.
    Investigational new drugs, 1997, Volume: 15, Issue:2

    Topics: Adenine; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Head

1997
Phase II study of amonafide in advanced pancreatic adenocarcinoma.
    Investigational new drugs, 1991, Volume: 9, Issue:4

    Topics: Adenine; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Imides

1991
Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer.
    Investigational new drugs, 1991, Volume: 9, Issue:1

    Topics: Adenine; Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Drug Evaluation; Humans; Imide

1991

Other Studies

38 other studies available for adenine and Adenocarcinoma, Basal Cell

ArticleYear
Modulation of protein S and growth arrest specific 6 protein signaling inhibits pancreatic cancer cell survival and proliferation.
    Oncology reports, 2020, Volume: 44, Issue:4

    Topics: Adenine; Adenocarcinoma; Apoptosis; Axl Receptor Tyrosine Kinase; c-Mer Tyrosine Kinase; Carcinoma,

2020
Targeting B cells in pancreatic adenocarcinoma: does RESOLVE resolve the question?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:5

    Topics: Adenine; Adenocarcinoma; Albumins; B-Lymphocytes; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pa

2021
The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer.
    Nature communications, 2021, 07-30, Volume: 12, Issue:1

    Topics: Adenine; Adenocarcinoma; Animals; Carcinogenesis; Cell Line, Tumor; Dual Specificity Phosphatase 6;

2021
Suppression of autophagy by CUB domain-containing protein 1 signaling is essential for anchorage-independent survival of lung cancer cells.
    Cancer science, 2013, Volume: 104, Issue:7

    Topics: Adenine; Adenocarcinoma; Adenocarcinoma of Lung; Anoikis; Antigens, CD; Antigens, Neoplasm; Autophag

2013
Optimization of global DNA methylation measurement by LC-MS/MS and its application in lung cancer patients.
    Analytical and bioanalytical chemistry, 2013, Volume: 405, Issue:27

    Topics: Adenine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Chromatography, Liquid; Deoxycytidine; DNA

2013
The role of autophagy induced by pemetrexed in lung adenocarcinoma cells.
    Oncology reports, 2014, Volume: 31, Issue:5

    Topics: Adenine; Adenocarcinoma; Adenocarcinoma of Lung; Annexin A5; Antimetabolites, Antineoplastic; Apopto

2014
Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:4

    Topics: Adenine; Adenocarcinoma; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Autophagy-R

2014
Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.
    Cancer research, 2015, Apr-15, Volume: 75, Issue:8

    Topics: Adenine; Adenocarcinoma; Animals; Antineoplastic Agents; Female; Fibrosis; Male; Mice; Mice, Inbred

2015
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
    Pancreas, 2015, Volume: 44, Issue:6

    Topics: Adenine; Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur L

2015
The essential role of methylthioadenosine phosphorylase in prostate cancer.
    Oncotarget, 2016, Mar-22, Volume: 7, Issue:12

    Topics: Adenine; Adenocarcinoma; Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Humans; Male; Me

2016
Resolution of lung adenocarcinoma after discontinuation of ibrutinib.
    BMJ case reports, 2016, Jul-18, Volume: 2016

    Topics: Adenine; Adenocarcinoma; Adenocarcinoma of Lung; Aged; Humans; Lung; Lung Neoplasms; Male; Piperidin

2016
Polymorphisms of XRCC1 gene and risk of gastric cardiac adenocarcinoma.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2009, Volume: 22, Issue:5

    Topics: Adenine; Adenocarcinoma; Adult; Aged; Arginine; Cardia; Case-Control Studies; Codon; Cytosine; DNA R

2009
Chromium (VI) induces both bulky DNA adducts and oxidative DNA damage at adenines and guanines in the p53 gene of human lung cells.
    Carcinogenesis, 2012, Volume: 33, Issue:10

    Topics: Adenine; Adenocarcinoma; Carcinogens, Environmental; Cell Line, Tumor; Chromium; DNA Adducts; DNA Da

2012
New ruthenium(II)-letrozole complexes as anticancer therapeutics.
    Journal of medicinal chemistry, 2012, Oct-25, Volume: 55, Issue:20

    Topics: Adenine; Adenocarcinoma; Antineoplastic Agents; Aromatase Inhibitors; Autophagy; Breast Neoplasms; C

2012
[The effect of autophagy on the radioresistance of human adenocarcinoma A549 cell in hypoxia condition].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2012, Volume: 15, Issue:11

    Topics: Adenine; Adenocarcinoma; Adenocarcinoma of Lung; Autophagy; Cell Hypoxia; Cell Line, Tumor; Gamma Ra

2012
Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells.
    Biochemical and biophysical research communications, 2013, Feb-08, Volume: 431, Issue:2

    Topics: Adenine; Adenocarcinoma; Autophagy; Autophagy-Related Protein 7; Cell Line, Tumor; Cell Survival; Dr

2013
Decreased repair activities of 1,N(6)-ethenoadenine and 3,N(4)-ethenocytosine in lung adenocarcinoma patients.
    Cancer research, 2003, Aug-01, Volume: 63, Issue:15

    Topics: Adenine; Adenocarcinoma; Adult; Age Factors; Aged; Cytosine; DNA Adducts; DNA Repair; DNA, Neoplasm;

2003
POTENTIAL PURINE ANTAGONISTS. 32. THE SYNTHESIS AND ANTITUMOR ACTIVITY OF CERTAIN COMPOUNDS RELATED TO 4-AMINOPYRAZOLO(3,4-D)PYRIMIDINE.
    Journal of medicinal and pharmaceutical chemistry, 1962, Volume: 5

    Topics: Adenine; Adenocarcinoma; Antineoplastic Agents; Chemical Phenomena; Chemistry; Pharmacology; Purines

1962
Cyclin D1 guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-20, Volume: 25, Issue:6

    Topics: Adenine; Adenocarcinoma; Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Cohort Studies; Cyclin D1;

2007
Some effects of inhibitors of polyamine synthesis on experimental prostatic cancer.
    Arzneimittel-Forschung, 1984, Volume: 34, Issue:1

    Topics: Adenine; Adenocarcinoma; Adenosylmethionine Decarboxylase; Animals; Carboxy-Lyases; Eflornithine; Gu

1984
Autophagic degradation of N-linked glycoproteins is downregulated in differentiated human colon adenocarcinoma cells.
    Biochemical and biophysical research communications, 1993, Dec-15, Volume: 197, Issue:2

    Topics: Adenine; Adenocarcinoma; Asparagine; Autophagy; Carbon Radioisotopes; Carcinogens; Cell Differentiat

1993
Mutational heterogeneity among individual tumors in a case of multiple primary malignancy of the colon.
    Japanese journal of clinical oncology, 1993, Volume: 23, Issue:6

    Topics: Adenine; Adenocarcinoma; Adenoma; Aged; Alleles; Base Sequence; Carcinoma; Codon; Colonic Neoplasms;

1993
High rate of multilocus deletion in a human tumor cell line.
    Human molecular genetics, 1993, Volume: 2, Issue:2

    Topics: Adenine; Adenine Phosphoribosyltransferase; Adenocarcinoma; Alleles; Base Sequence; Cell Transformat

1993
Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type.
    Cancer, 1993, Jun-15, Volume: 71, Issue:12

    Topics: Adenine; Adenocarcinoma; Aspartic Acid; Biology; Codon; Colonic Neoplasms; Gene Frequency; Genes, ra

1993
A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma.
    Biochemical and biophysical research communications, 2000, Nov-30, Volume: 278, Issue:3

    Topics: 3T3 Cells; Adenine; Adenocarcinoma; Animals; Base Sequence; Cell Transformation, Neoplastic; Colonic

2000
Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:6

    Topics: Adenine; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Alleles; Amino Acid Sequence;

2001
Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer.
    American journal of clinical oncology, 1991, Volume: 14, Issue:2

    Topics: Adenine; Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Evaluatio

1991
Alpha 2-adrenergic receptor-mediated sensitization of forskolin-stimulated cyclic AMP production.
    Proceedings of the National Academy of Sciences of the United States of America, 1987, Volume: 84, Issue:5

    Topics: Adenine; Adenocarcinoma; Adrenergic alpha-Antagonists; Brimonidine Tartrate; Cell Line; Colforsin; C

1987
[Individual sensitivity of ovarian ascitic cancer to thiophosphamide].
    Voprosy onkologii, 1974, Volume: 20, Issue:8

    Topics: Adenine; Adenocarcinoma; Ascites; Ascitic Fluid; Carbon Radioisotopes; Carcinoma; Carcinoma, Papilla

1974
In vitro demonstration of iodide-trapping defect but normal thyrotropin (TSH) responsiveness in benign and malignant "cold" thyroid nodules.
    Transactions of the Association of American Physicians, 1972, Volume: 85

    Topics: Adenine; Adenocarcinoma; Adenoma; Adenylyl Cyclases; Carbon Dioxide; Carbon Isotopes; Colloids; Cycl

1972
Studies on the nucleic acid metabolism of renal tumour cells in vitro.
    Urological research, 1974, Volume: 2, Issue:1

    Topics: Adenine; Adenocarcinoma; Carbon Radioisotopes; Carcinoma, Transitional Cell; Cells, Cultured; DNA, N

1974
Nonspecific inhibition of precursor uptake by alkyl-substituted purines and prednisolone.
    Chemico-biological interactions, 1974, Volume: 9, Issue:4

    Topics: Acetates; Adenine; Adenocarcinoma; Animals; Carbon Radioisotopes; Cell Division; Cell Line; Choline;

1974
Inhibition of guanine metabolism of mammalian tumor cells by the carbocyclic analogue of adenosine.
    Molecular pharmacology, 1971, Volume: 7, Issue:4

    Topics: Adenine; Adenocarcinoma; Adenosine; Carbon Isotopes; Cells, Cultured; Chromatography, Paper; Cyclope

1971
Determination of individual human tumour sensitivity to antitumour agents by tissue-slice incubation.
    Canadian journal of surgery. Journal canadien de chirurgie, 1971, Volume: 14, Issue:6

    Topics: Adenine; Adenocarcinoma; Antineoplastic Agents; Carbon Isotopes; Carcinoma; Colonic Neoplasms; Cultu

1971
Hypoxanthine phosphoribosyltransferase and guanine metabolism of adenocarcinoma 755 cells.
    Biochemical pharmacology, 1970, Volume: 19, Issue:2

    Topics: Adenine; Adenocarcinoma; Buffers; Carbon Isotopes; Guanine; Hydrogen-Ion Concentration; Hypoxanthine

1970
Feedback inhibition of purine biosynthesis in adenocarcinoma 755 and sarcoma 180 cells in culture.
    Journal of the National Cancer Institute, 1970, Volume: 45, Issue:4

    Topics: Adenine; Adenocarcinoma; Animals; Azaserine; Carbon Isotopes; Cell Line; Feedback; Hypoxanthines; Me

1970
Reversal of the growth inhibitory effects of 6-methylthiopurine ribonucleoside.
    Biochemical pharmacology, 1970, Volume: 19, Issue:6

    Topics: Adenine; Adenocarcinoma; Animals; Cell Division; Cell Line; Guanine; Hypoxanthines; Imidazoles; Mice

1970
Purine N-oxides. XVI. Oncogenic derivatives of xanthine and guanine.
    Cancer research, 1965, Volume: 25, Issue:7

    Topics: Adenine; Adenocarcinoma; Animals; Carcinogens; Carcinoma, Squamous Cell; Female; Fibroblasts; Fibros

1965